Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with Abiraterone in Bone Metastatic CRPC
NCT01650194Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2012
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Started Jul 2012; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01650194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650194.